Moxifloxacin in the treatment of skin and skin structure infections

Therapeutics and Clinical Risk Management

Volumn 2, Issue 4, 2006, Pages 417-434

  Guay, David R P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cellulitis; Fluoroquinolones; Moxifloxacin; Skin infections; Skin ulcers

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFALEXIN; CEFUROXIME; CIPROFLOXACIN; DOXYCYCLINE; GATIFLOXACIN; GLIBENCLAMIDE; LEVOFLOXACIN; LOMEFLOXACIN; METHYLXANTHINE DERIVATIVE; METICILLIN; METRONIDAZOLE; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; PENTAMIDINE; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; RIFAPENTINE; SPARFLOXACIN; TEICOPLANIN; TEMAFLOXACIN; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN; WARFARIN;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL STRAIN; BONE INFECTION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; GASTROINTESTINAL TOXICITY; GLUCOSE METABOLISM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; INSOMNIA; LIVER FAILURE; MICROBIAL ACTIVITY; MILK; MONOTHERAPY; NAUSEA; NONHUMAN; PHOTOTOXICITY; POSTMARKETING SURVEILLANCE; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SKIN TOXICITY; SOFT TISSUE INFECTION; SYNCOPE; TACHYCARDIA; TASTE DISORDER; TOXIC EPIDERMAL NECROLYSIS; VAGINA CANDIDIASIS; VAGINITIS; VOMITING; WOUND INFECTION;

EID: 33845459629     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.4.417     Document Type: Review

References (116)

1. Ackermann G, Schaumann R, Pless B, et al. 2000. Comparative activity of moxifloxacin in vitro against obligately anerobie bacteria. Eur J Clin Microbiol Infect Dis, 19:228-32.
2. Alcaide F, Calatayud L, Santin M, et al. 2004. Comparative in vitro activities of linezolid, telithromyein, clarithromyein, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother, 48:4562-5.
3. Aldridge KE, Ashcraft DS. 1997. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother, 41:709-11.
4. Amabile-Cuevas CF, Hermida-Escobedo C, Vivar R. 2001. Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes. Clin Infect Dis, 32(Suppl 1):S30-2.
5. Andriole VT, Haverstock DC, Choudhri SH. 2005. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Safety, 28:443-52.
6. Anonymous. 2005. Avelox® (moxifloxacin) product information. Bayer HealthCare, West Haven, CT, June 2005.
7. Aubry A, Jarlier V, Escolano S, et al. 2000. Antibiotic susceptibility pattern of Mycobacterium marinum. Antimicrob Agents Chemother, 44:3133-6.
8. Ball P, Stahlmann R, Kubin R, et al. 2004. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther, 26:940-50.
9. Ballow C, Lettieri J, Agarwal V, et al. 1999. Absolute bioavailability of moxifloxacin. Clin Ther, 21: 513-22.
10. Barry AL, Fuchs PC, Brown SD. 1999. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests. Eur J Clin Microbiol Infect Dis, 18:305-9.
11. Bauernfeind A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxaein. J Antimicrob Chemother, 40:639-51.
12. Betriu C, Gomez M, Palau ML, et al. 1999. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. Antimicrob Agents Chemother, 43:2320-2.
13. Betriu C, Rodriguez-Avial I, Gomez M, et al. 2005. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002). Diagn Microbiol Infect Dis, 53:221-3.
14. Biedenbach DJ, Toleman MA, Walsh TR, et al. 2006. Characterization of fluoroquinolone-resistant β-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobiol Surveillance Program (1997-2004). Diagn Microbiol Infect Dis, 55:119-27.
15. Blondeau JM, Laskowski R, Bjarnason J, et al. 2000. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 gram-negative and gram-positive organisms. Int J Antimicrob Agents, 14:45-50.
16. Blondeau JM. 2002. The role of fluoroquinolones in skin and skin structure infections. Am J Clin Dermatol, 3:37-46.
17. Bogdanovich T, Esel D, Kelly LM, et al. 2005. Antistaphylococcal activity of DX-169, a new des-F(6)-quinolone, compared with those of other agents. Antimicrob Agents Chemother, 49:3325-33.
18. Boswell FJ, Andrews JM, Wise R. 1997. Pharmacodynamic properties of Bay 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. Antimicrob Agents Chemother, 41:1377-9.
19. Bowker KE, Noel AR, MacGowan AP. 2003. In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. Int J Antimicrob Agents, 22:557-61.
20. Braback M, Riesbeck K, Forsgren A. 2002. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared with its susceptibilities to reference macrolides and quinolones. Antimicrob Agents Chemother, 46:1114-16.
21. Burkhardt O, Borner K, Stass H, et al. 2002. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis, 34:898-903.
22. Burkhardt O, Stass H, Thuss U, et al. 2005. Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. Clin Pharmacokinet, 44:969-76.
23. Chen X, Cass JD, Bradley JA, et al. 2005. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol, 146:792-9.
24. Credito KL, Jacobs MR, Appelbaum PC. 2003. Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents. Antimicrob Agents Chemother, 47:1399-402.
25. Critchley IA, Sahm DF, Thornsberry C, et al. 2002. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999. Diagn Microbiol Infect Dis, 42:129-35.
26. Dalhoff A, Petersen U, Endermann R. 1996. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Chemotherapy, 42:410-25.
27. Dalhoff A, Schubert S, Ullmann U. 2005. Effect of pH on the in vitro activity of and propensity for the emergence of resistance to fluoroquinolones, macrolides, and a ketolide. Infection, 33(suppl 2):36-43.
28. Dan M, Keynan O, Feldbrin Z, et al. 2004. Concentrations of moxifloxacin in serum and synovial fluid, and ex vivo bactericidal activity against arthritis-causing pathogens. Diagn Microbiol Infect Dis, 48:283-6.
29. Draenert R, Kunzelmann M, Roggenkamp A, et al. 2005. Infected cat-bite wound treated successfully with moxifloxacin after failure of parenteral cefuroxime and ciprofloxacin. Eur J Clin Microbiol Infect Dis, 24:288-90.
30. Duncan K, Barry CE 3rd. 2004. Prospects for new antitubercular drugs. Curt Opin Microbiol, 7:460-5.
31. Edlund C, Sabouri S, Nord CE. 1998. Comparative in vitro activity of BAY 12-8039 and five other antimierobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis, 17:193-5.
32. Edmiston CE, Krepel CJ, Seabrook GR, et al. 2004. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother, 48:1012-16.
33. Edmiston CE, Krepel CJ, Kehl KS, et al. 2005. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic, and otolaryngologic surgical patients. J Antimicrob Chemother, 56:872-8.
34. Ednie LM, Rattan A, Jacobs MR, et al. 2003. Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents. Antimicrob Agents Chemother, 47:1143-7.
35. Elbe DH, Chang SW. 2005. Moxifloxacin-warfarin interaction: a series of five case reports. Ann Pharmacother, 39:361-4.
36. Esposito S, Noviello S, Ianniello F. 2000. Bactericidal activity of moxifloxacin compared with grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model. J Chemother, 12:475-81.
37. Fass RJ. 1997. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother, 41:1818-24.
38. Fuhrmann V, Schenk P, Jaeger W, et al. 2004. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous hemodiafiltration. J Antimicrob Chemother, 54:780-4.
39. Fung-Tomc JC, Minassian B, Kolek B, et al. 2000. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother, 44:3351-6.
40. Gavin JR 3rd, Kubin R, Choudhri S, et al. 2004. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Safety, 27:671-86.
41. Gillespie SH, Billington O. 1999. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother, 44:393-5.
42. Giordano P, Song J, Pentel P, et al. 2005. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents, 26:357-65.
43. Golan Y, McDermott LA, Jacobus NV, et al. 2003. Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother, 52:208-13.
44. Goldstein EJ, Citron DM, Hudspeth M, et al. 1997. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared with the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob Agents Chemother, 41:1552-7.
45. Goldstein EJ, Citron DM, Merriam CV, et al. 2000. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother, 44:2747-51.
46. Goldstein EJ, Citron DM, Merriam CV, et al. 2002. In vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine Pasteurella species. Antimicrob Agents Chemother, 46:3068-70.
47. Goldstein EJ, Citron DM, Warren YA, et al. 2006. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother, 50:148-55.
48. Guay DRP. 2005. Chapter 8. Quinolones. In: Piscitelli SC, Rodvold KA (eds). Infectious disease: drug interactions in infectious diseases. 2nd ed. Totowa, NJ: Humana Pr. p 215-54.
49. Hardy D, Amsterdam D, Mandell LA, et al. 2000. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. Antimicrob Agents Chemother, 44:802-5.
50. Hedberg M, Nord CE, ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. 2003. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect, 9:475-88.
51. Hermsen ED, Hovde LB, Sprandel KA, et al. 2005. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother, 49:685-9.
52. Hoellman DB, Kelly LM, Jacobs MR, et al. 2001. Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother, 45:589-92.
53. Hoogkamp-Korstanjc JA, Roelofs-Willemse J. 2000. Comparative in vitro activity of moxifloxacin against gram-positive clinical isolates. J Antimicrob Chemother, 45:31-9.
54. Hsueh PR, Teng LJ, Lee CM et al. 2003. Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data. Antimicrob Agents Chemother, 47:2152-7.
55. Ince D, Zhang X, Hooper DC. 2003. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob Agents Chemother, 47:1410-15.
56. Jacobs MR, Bajaksouzian S, Windau A, et al. 2004. In vitro activity of the new quinolone WCK 771 against staphylococci. Antimicrob Agents Chemother, 48:3338-42.
57. Ji B, Grosset J. 2000. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Leprosy Rev, 71(Suppl):S81-7.
58. Joukhadar C, Stass H, Muller-Zellenberg U, et al. 2003. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother, 47:3099-103.
59. Kalteis T, Beckmann J, Schroder H-J, et al. 2006a. Moxifloxacin superior to vancomycin for treatment of bone infections - a study in rats. Acta Orthoped, 77:315-19.
60. Kalteis T, Beckmann J, Sehroder H-J, et al. 2006b. Treatment of implant-associated infections with moxifloxacin: an animal study. Int J Antimicrob Agents, 27:444-8.
61. Labombardi VJ, Shastry L, Tischler H. 2005. Mycobacterium thermoresistibile infection following knee-replacement surgery. J Clin Microbiol, 43:5393-4.
62. Leal del Rosal P, Fabian G, Vick-Fragaso R, et al. 1999. Efficacy and safety of moxifloxacin (MXF) vs. cephalexin (with or without metronidazole) in the treatment of mild to moderate uncomplicated skin and skin structure infections (uSSSI) [abstract]. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, Sept. 26-29. 1076.
63. Leal del Rosal P, Martinez R, Fabian G, et al. 1999. Efficacy and safety of moxifloxacin vs. cephalexin in the treatment of mild to moderate uncomplicated skin and skin structure infections (USSSI). J Antimicrob Chemother, 44(suppl A): 148. P493.
64. Lemmen SW, Hafner H, Klik S, et al. 2003. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae. Chemotherapy, 49:33-5.
65. Lettieri J, Vargas R, Agarwal V, et al. 2001. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. Clin Pharmacokinet, 40 (Suppl 1): 19-25.
66. Lion C, Conroy MC, Carpentier AM, et al. 2006. Antimicrobial susceptibilities of Pasturella strains isolated from humans. Int J Antimicrob Agents, 27:290-3.
67. Lister PD. 2001. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis, 32(Suppl 1):S33-8.
68. Lubasch A, Keller I, Borner K, et al. 2000. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother, 44:2600-3.
69. MacGowan AP, Bowker KE, Holt HA, et al. 1997. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. J Antimicrob Chemother, 40:503-9.
70. Malathum K, Singh KV, Murray BE. 1999. In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteria. Diagn Microbiol Infect Dis, 35:127-33.
71. Malincarne L, Ghebregzabher M, Moretti MV, et al. 2006. Penetration of moxifloxacin into bone in patients undergoing total knee arthoplasty. J Antimicrob Chemother, 57:950-4.
72. Man I, Murphy J, Ferguson J. 1999. Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. J Antimicrob Chemother, 43 (Suppl B):77-82.
73. Mandell GL, Coleman E. 2001. Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother, 45:1794-8.
74. Milatovic D, Schmitz FJ, Brisse S, et al. 2000. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother, 44:1102-7.
75. Mitscher L. 2005. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev, 105:559-92.
76. Morganroth J, DiMarco JP, Anzueto A, et al; CAPRIE Study Group. 2005. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs. levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest, 128:3398-406.
77. Muller M, Stass H, Brunner M, et al. 1999. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother, 43:2345-9.
78. Noel AR, Bowker KN, MacGowan AP. 2005. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. Antimicrob Agents Chemother, 49:4234-9.
79. Norl S, Nebesio C, Brashear R, et al. 2004. Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure (letter). Arch Dermatol, 140:1537-8.
80. Noviello S, Ianniello F, Leone S, et al. 2003. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens. J Antimicrob Chemother, 52:869-71.
81. Odenholt I, Lowdin E, Gustafsson I, et al. 2002. Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model. Antimicrob Agents Chemother, 46:2046-8.
82. Parish LC, Routh HB, Miskin B, et al. 2000. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections, Int J Clin Prac, 54:497-503.
83. Park-Wyllie LY, Juurlink DN, Kopp A, et al. 2006. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med, 354:1352-61.
84. Patel MV, De Souza NJ, Gupte SV, et al. 2004. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother, 48:4754-61.
85. Pea F, Pavan F, Lugatti E, et al. 2006. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. Clin Pharmacokinet, 45:287-95.
86. Perez-Giraldo C, Gonzalez-Velasco C, Sanchez-Silos RM, et al. 2004. Moxifloxacin and biofilm production by coagulase-negative staphylococci. Chemotherapy, 50:101-4.
87. Peric M, Jacobs MR, Appelbaum PC. 2004. Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared with those of nine other agents. Antimicrob Agents Chemother, 48:3188-92.
88. Raghavan M, Linden PK. 2004. Newer treatment options for skin and soft tissue infections. Drugs, 64:1621-42.
89. Rodrlguez Diaz JC, Lopez M, Ruiz M, et al. 2003. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents, 21:585-8.
90. Rubinstein E, Diamantstein L, Yoseph G, et al. 2000. The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. Clin Microbiol Infect, 6:678-81.
91. Ruiz J. 2003. Mechanism of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother, 51:1109-17.
92. Sable D, Mumkawa GJ. 2003. Quinolones in dermatology. Clin Dermatol, 21:56-63.
93. Schaumann R, Ackermann G, Pless B, et al. 2000. In vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteria. Int J Antimicrob Agents, 16:225-32.
94. Schaumann R, Goldstein EJC, Forberg J, et al. 2005. Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures, J Med Microbiol, 54:749-53.
95. Seral C, Van Bambeke F, Tulkens PM. 2003. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother, 47:2283-92.
96. Sillerstrom E, Wahlund E, Nord CE. 2004. In vitro activity of ABT-492 against anaerobic bacteria. J Chemother, 16:227-9.
97. Snydman DR, Jacobus NV, McDermott LA, et al. 2002. In vitro activities of newer quinolones against Bacteroides group organisms. Antimicrob Agents Chemother, 46:3276-9.
98. Speciale A, Musumeci R, Blandino G, et al. 2002. Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates, Int J Antimicrob Agents, 19:111-18.
99. Stass H, Dalhoff A, Kubitza D, et al. 1998. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother, 42:2060-5.
100. Stass H, Kubitza D. 1999. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother, 43(Suppl B):83-90.
101. Stass H, Kubitza D, Schuhly U. 2001. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet, 40(Suppl 1): 1-9.
102. Stass H, Kubitza D, Halabi A. 2002. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol, 53:232-7.
103. Stass H, Nagelschmitz J, Moeller JG, et al. 2004. Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200mg oral itraconazole given once a day in healthy subjects. Int J Clin Pharmacol Ther, 42:23-9.
104. Stefanopoulos PK, Tarantzopoulou AD. 2005. Facial bite wounds: management update, Int J Oral Maxillofac Surg, 34:464-72.
105. Stevens DL, Bisno AL, Chambers HF, et al. 2005. Practice guidelines for the diagnosis and management of skin and soil-tissue infections. Clin Infect Dis, 41:1373-406.
106. Stratchounski LS, Dekhnich AV, Kretchikov VA, et al. 2005. Antimicrobial resistance of nosocomial strains of Staphylococcus aureus in Russia: results of a prospective study. J Chemother, 17:54-60.
107. Sullivan JT, Woodruff M, Lettieri J, et al. 1999. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother, 43:2793-7.
108. Sullivan JT, Lettieri JT, Liu P, et al. 2001. The influence of age and gender on the pharmacokinetics of moxifloxacin. Clin Pharmacokinet, 40(Suppl 1):11-18.
109. Tarasi A, Cassone M, Monaco M, et al. 2003. Activity of moxifloxacin in combination with vancomycin or teieoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy. J Chemother, 15:239-43.
110. Tzikouris JP, Peeters MJ, Cox CD, et al. 2006. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol, 11:52-6.
111. von Eiff C, Peters G. 1999. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother, 43:569-73.
112. Wenzler S, Schmidt-Eisenlohr E, Daschner F. 2004. Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections. Chemotherapy, 50:40-2.
113. Wise R, Andrews JM, Marshall G, et al. 1999. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother, 43:1508-10.
114. Woodcock JM, Andrews JM, Boswell FJ, et al. 1997. In vitro activity of Bay 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother, 41:101-6.
115. Wright DH, Gunderson BW, Hovde LB, et al. 2002. Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions. Antimicrob Agents Chemother, 46:1561-3.
116. Yang SC, Hsueh PR, Lai HC, et al. 2003. High prevalence of antimicrobial resistance in rapidly growing myeobacteria in Taiwan. Antimicrob Agents Chemother, 47:1958-62.